, Volume 118, Issue 8, pp 1255-1259

Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study

Purchase on Springer.com

$39.95 / €34.95 / £29.95*

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer’s disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this ‘real-life’ setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.